Stelios Papadopoulos's Trading History
| EXELExelixis | May 29, 2026 | Director | Uninformative Buy | ― | $83.10M | |
| OVIDOvid Therapeutics | Apr 09, 2026 | Director | Uninformative Buy | 45.00K | $552.65K | |
| RGLSRegulus | Jun 27, 2025 | ― | Uninformative Sell | ― | $0.00 | |
| BIIBBiogen | Jun 17, 2022 | Director | Uninformative Buy | ― | $9.71M | |
| BGMDBG Medicine | Feb 01, 2013 | Director | Informative Buy | 500.00K | ― | |
| GNVCGenVec Inc | ― | ― | ― | $2.20M |
You May Also Like
Stelios Papadopoulos insider profile FAQ
What is the percentage of profitable transactions made by Stelios Papadopoulos?
The percentage of profitable transactions made by Stelios Papadopoulos is 38%.
What is the average return per transaction made by Stelios Papadopoulos?
The average return per transaction made by Stelios Papadopoulos is -19.80%.
What stocks does Stelios Papadopoulos hold?
Stelios Papadopoulos holds: EXEL, OVID, BIIB, RGLS, GNVC, BGMD stocks.
What was Stelios Papadopoulos's most profitable transaction?
Stelios Papadopoulos’s most profitable transaction was an Informative Sell of EXEL stock on September 20, 2017. The return on the trade was 40.20%.
What is Stelios Papadopoulos's role in Exelixis?
Stelios Papadopoulos's role in Exelixis is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.